Is Century Therapeutics, Inc. overvalued or undervalued?

As of 16 May 2022, the valuation grade for Century Therapeutics, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company is currently assessed as overvalued. Key ratios include a price-to-book value of 0.22, an EV to EBITDA ratio of 6.45, and a negative ROE of -7.99%.
In comparison to peers, Trevi Therapeutics, Inc. has a P/E ratio of -15.40 and an EV to EBITDA of -12.29, while Vaxart, Inc. also falls into the risky category with a P/E of -2.34 and an EV to EBITDA of -1.92. The stark contrast in performance and valuation metrics among these companies suggests that Century Therapeutics, Inc. is not positioned favorably within its industry. Additionally, the company's stock has significantly underperformed relative to the S&P 500, with a year-to-date decline of 43.07% compared to a 2.44% gain for the index.